Biodesix IncBDSX

BiodeSIX Inc’s latest SEC filing reads like a business built on high-sounding language and modest numbers. In the three months to March 31 2026, the company reported revenues of $25.6 million, a net loss attributable to parent of $7.8 million, and an operating loss of $6.2 million, all from its pair of revenue lines: Biodesix Diagnostic Tests and Biodesix Development Services. Medicare picked up 32% of the revenue in the quarter, down from 36% a year earlier, a detail that only appears in the footnotes rather than the polished brochures. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1439725/000119312526203960/bdsx-20260331.htm)

The Diagnostic Tests are five blood-based lung diagnostic tests that healthcare providers order, while the Development Services are end-to-end assay development and validation for biopharma and academic partners. The company says its Development Services have been utilised by “over 65 industry clients and academic partners,” which is corporate speak for “we’ll run your assays for you.” The deferred revenue of $0.2 million on the March 31 balance sheet is the only part expected to convert to cash within twelve months, a polite way of noting that this may be the only line item that actually pays the rent. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1439725/000119312526203960/bdsx-20260331.htm)

Cash and cash equivalents stood at $25.6 million at March 31 2026, but the net cash used in operating activities was $10.2 million, a number that rarely gets centre stage in the “partner with us to accelerate your research” slide. The weighted average diluted shares outstanding sat at 9.7 million, and the loss per diluted share was $0.81, which is dilution talking rather than momentum. The company’s filings describe two revenue streams-Diagnostic Tests and Development Services-but the balance sheet is still doing the talking. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1439725/000119312526203960/bdsx-20260331.htm)

The latest 424B3 filing confirms that the company derives revenue from (i) Diagnostic Tests, providing lung diagnostic testing services for healthcare providers, and (ii) Development Services enabling biopharmaceutical and research institutions. The same filing notes that Development Services have been used by “over 65 industry clients and academic partners,” a line that could just as well read “we’ll run your assays for you.” The filing also explains that deferred revenue of $0.2 million is expected to be recognised in revenues over the next twelve months as test results are delivered and services are performed. (source: SEC EDGAR 424B3, https://www.sec.gov/Archives/edgar/data/1439725/000119312526248913/d134053d424b3.htm)

If you are looking for a chart route, the FreedomCore chart rail for BDSX on the regional exchange is available here: https://www.tradingview.com/chart/?symbol=BDSX. The chart rail carries only price and volume; no analyst levels, support, resistance, or moving averages are implied or intended.

The company’s 10-Q shows stockholders’ equity attributable to parent of $9.1 million against liabilities of $85.5 million, a capital structure that leaves little room for balance-sheet theatrics. Net cash provided by operating activities was negative $10.2 million, and the payments to acquire property, plant and equipment were a trifling $81,000, which tells you all the source requires readers to know about capital intensity versus cash burn. Research and development expense was $3.3 million in the quarter-substantial in absolute terms, but modest relative to the operating loss. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1439725/000119312526203960/bdsx-20260331.htm)

What we do not yet know is how quickly the deferred revenue converts to cash, how stable the mix between Medicare and other payors will be, and whether the Development Services pipeline can scale beyond the 65 named partners without additional capital. The next 10-Q will show whether the operating loss is narrowing or widening, and whether the cash runway is extending or contracting. Until then, the story remains one of modest revenues, persistent losses, and a balance sheet that is still finding its footing. (source: SEC EDGAR filings, https://www.sec.gov/edgar/browse/?CIK=1439725)